These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 28434150)

  • 21. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.
    Guenancia C; Ladoire S; Ghiringelli F; Rochette L; Vergely C; Cottin Y
    Arch Cardiovasc Dis; 2017 Feb; 110(2):69-71. PubMed ID: 28216265
    [No Abstract]   [Full Text] [Related]  

  • 22. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy.
    Katsurada K; Ichida M; Sakuragi M; Takehara M; Hozumi Y; Kario K
    Springerplus; 2014; 3():620. PubMed ID: 25392790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
    El-Sherbeny WS; Sabry NM; Sharbay RM
    J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
    Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
    ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
    Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity.
    Mornoş C; Manolis AJ; Cozma D; Kouremenos N; Zacharopoulou I; Ionac A
    Hellenic J Cardiol; 2014; 55(3):235-44. PubMed ID: 24862616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
    Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
    Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
    Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J
    Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
    Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
    Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
    Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
    PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.
    Bisoc A; Ciurescu D; Rădoi M; Tântu MM; Rogozea L; Sweidan AJ; Bota DA
    Am J Ther; 2020; 27(2):e142-e150. PubMed ID: 30648987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy.
    Advani P; Hoyne J; Moreno-Aspita A; Dubin M; Brock S; Harlow C; Chumsri S; Suter T; Blackshear JL
    Chemotherapy; 2017; 62(6):334-338. PubMed ID: 28704807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
    Feng Y; Qin Z; Yang Z
    J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
    Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
    Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.